Quince Therapeutics, Inc. (QNCX)
Total Valuation
QNCX has a market cap or net worth of $39.30 million. The enterprise value is -$43.15 million.
| Market Cap | 39.30M |
| Enterprise Value | -43.15M |
Important Dates
The next estimated earnings date is Tuesday, December 5, 2023, after market close.
| Earnings Date | Dec 5, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 42.87 million shares outstanding. The number of shares has increased by 1.29% in one year.
| Shares Outstanding | 42.87M |
| Shares Change (YoY) | +1.29% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 21.65% |
| Owned by Institutions (%) | 25.25% |
| Float | 31.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.49 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 37.80, with zero debt.
| Current Ratio | 37.80 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.10% and return on invested capital (ROIC) is -37.23%.
| Return on Equity (ROE) | -31.10% |
| Return on Assets (ROA) | -30.20% |
| Return on Capital (ROIC) | -37.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $320,000 in taxes.
| Income Tax | 320,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.31% in the last 52 weeks. The beta is 1.34, so QNCX's price volatility has been higher than the market average.
| Beta (1Y) | 1.34 |
| 52-Week Price Change | +31.31% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.28 |
| Relative Strength Index (RSI) | 46.81 |
| Average Volume (30 Days) | 92,133 |
Short Selling Information
The latest short interest is 2.18 million, so 5.08% of the outstanding shares have been sold short.
| Short Interest | 2.18M |
| Short Previous Month | 2.16M |
| Short % of Shares Out | 5.08% |
| Short % of Float | 6.99% |
| Short Ratio (days to cover) | 40.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.95M |
| Pretax Income | -27.71M |
| Net Income | -28.03M |
| EBITDA | -27.65M |
| EBIT | -27.71M |
| Earnings Per Share (EPS) | -$0.76 |
Balance Sheet
The company has $83.73 million in cash and no debt, giving a net cash position of $83.73 million or $1.95 per share.
| Cash & Cash Equivalents | 83.73M |
| Total Debt | n/a |
| Net Cash | 83.73M |
| Net Cash Per Share | $1.95 |
| Equity / Book Value | 83.13M |
| Book Value Per Share | 1.94 |
| Working Capital | 82.92M |
Cash Flow
In the last 12 months, operating cash flow was -$18.05 million and capital expenditures -$124,000, giving a free cash flow of -$18.17 million.
| Operating Cash Flow | -18.05M |
| Capital Expenditures | -124,000 |
| Free Cash Flow | -18.17M |
| FCF Per Share | -$0.50 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -69.07% |
| FCF Yield | -44.79% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.29% |
| Shareholder Yield | -1.29% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |